Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Agios Pharmaceuticals, Inc.

https://www.agios.com/

Latest From Agios Pharmaceuticals, Inc.

Advanced Therapies From Orchard & Kite Win EMA Thumbs Up

Novartis’s siRNA for lowering cholesterol was also among the 10 new medicines that the European Medicines Agency this week said should be approved in the EU.

Europe Approvals

EMA: Moment Of Truth For Two Curative Therapies & A Possible Cholesterol-Lowering Blockbuster

The sponsors of 11 new treatments should learn this week whether the European Medicines Agency will recommend EU marketing approval for their products.

Europe Approvals

Sanofi Seeks Double Vaccine Approval Nod In EU

The sponsors of up to seven new drugs or vaccines will find out this week whether their products will soon be approved in the EU. The products include two vaccines from Sanofi and what is possibly the first generic rival to Bayer's Xarelto to be assessed by the European Medicines Agency.

Drug Review Europe

Bristol/Agios AML’s Idhifa Fails In Phase III, But Approval Seems Secure

Idhifa is already approved in the US for relapsed or refractory AML patients with IDH2 mutations based on Phase I/II complete responses, but did not meet the overall survival endpoint in the Phase III IDHENTIFY.

Drug Approval Standards Clinical Trials
See All

Company Information

  • Industry
  • Pharmaceuticals
UsernamePublicRestriction

Register